Invitae Corp (NYSE:NVTA) shares traded 16.12% higher at $0.60 on Wall Street last session.
In accordance with the data, 9 analysts cover Invitae Corp (NYSE:NVTA). The consensus rating among analysts is ‘Underweight’. As we calculate the median target price by taking the range between a high of $4.00 and a low of $0.30, we find $0.75. Given the previous closing price of $0.52, this indicates a potential upside of 44.23 percent. NVTA stock price is now -9.49% away from the 50-day moving average and -50.49% away from the 200-day moving average. The market capitalization of the company currently stands at $171.89M.
It has been rated a hold by 5 analysts and a buy by 0. Brokers who have rated the stock have averaged $1.31 as their price target over the next twelve months.
In other news, Nussbaum Robert L, Chief Medical Officer sold 7,086 shares of the company’s stock on Jun 13. The stock was sold for $9,757 at an average price of $1.38. Upon completion of the transaction, the Chief Medical Officer now directly owns 569,345 shares in the company, valued at $0.34 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 13, Brida Thomas sold 7,079 shares of the business’s stock. A total of $9,748 was realized by selling the stock at an average price of $1.38. This leaves the insider owning 704,087 shares of the company worth $0.42 million. Insiders disposed of 286,719 shares of company stock worth roughly $0.17 million over the past 1 year. A total of 2.94% of the company’s stock is owned by insiders.
Invitae Corp (NYSE: NVTA) opened at $0.5450 on Tuesday. During the past 12 months, Invitae Corp has had a low of $0.36 and a high of $3.68. The fifty day moving average price for NVTA is $0.6630 and a two-hundred day moving average price translates $1.2119 for the stock.
The latest earnings results from Invitae Corp (NYSE: NVTA) was released for Sep, 2023. According to the Diagnostics & Research Company, earnings per share came in at -$0.1, beating analysts’ expectations of -$0.32 by 0.22. This compares to -$1.27 EPS in the same period last year. The net profit margin was -299.14% and return on equity was -863.95% for NVTA. The company reported revenue of $121.24 million for the quarter, compared to $133.54 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -9.21 percent. For the current quarter, analysts expect NVTA to generate $125.39M in revenue.
Invitae Corp(NVTA) Company Profile
Invitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women’s health, rare diseases, and pharmacogenomics; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.